Selegiline (CAS 14611-51-9) Suppliers and Product Information

Selegiline is a selective inhibitor of monoamine oxidase B (MAO-B) used in the treatment of Parkinson's disease. It suppresses dopamine inactivation processes and facilitates an increase of its level in the brain. Selegiline is FDA approved as an adjunct treatment in the management of patients with Parkinson's disease and as a treatment for major depressive disorder (MDD) in ***s.

Frequently Asked Questions about Selegiline

Q: What is the main use of Selegiline?

A: Selegiline is primarily used in the treatment of Parkinson's disease, either as monotherapy in early stages or in combination with levodopa/carbidopa in later stages. It is also used for treating major depressive disorder in ***s.

Q: How does Selegiline work?

A: Selegiline works by inhibiting monoamine oxidase B (MAO-B), an enzyme responsible for breaking down dopamine in the brain. By inhibiting this enzyme, Selegiline helps increase dopamine levels, which can improve symptoms of Parkinson's disease.

Q: Are there any dietary restrictions when taking Selegiline?

A: At recommended doses, Selegiline generally does not require dietary restrictions. However, at higher doses, it may inhibit MAO-A, which could increase the risk of interactions with tyramine-rich foods. It's always best to consult with a healthcare provider for specific dietary advice.

Q: What are the potential side effects of Selegiline?

A: Common side effects may include nausea, dizziness, insomnia, and dry mouth. Most adverse reactions are related to increased dopamine levels. Serious side effects are rare but can occur, especially when combined with certain other medications.